Physician profile
Ayse B Wise
NPI 1538215769
$7,219.10
in general payments reported to CMS, 2019-2025
25 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $1,541 · 2023: $1,533 · 2024: $1,659 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,911.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,090.44 | 2021-2025 | Caplyta |
| Abbvie INC. | $777.74 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $744.74 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $723.26 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $639.68 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $559.20 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $420.73 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $411.42 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $404.19 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $297.59 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $206.88 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $171.57 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $160.82 | 2021-2023 | Trintellix |
| Tris Pharma INC | $138.06 | 2021-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $136.36 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $94.76 | 2024 | Cobenfy |
| Adlon Therapeutics L.P. | $62.55 | 2021 | |
| Sunovion Pharmaceuticals INC. | $52.41 | 2021 | |
| Jazz Pharmaceuticals INC. | $25.41 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $24.50 | 2025 | Neffy |
| Alfasigma USA, INC. | $21.77 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.28 | 2025 | |
| Neos Therapeutics, LP | $14.25 | 2025 | Exxua |
| Almatica Pharma LLC | $14.11 | 2025 | Loreev Xr |
| Eisai INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayse Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.